Novel NLR-Based Prognostic Model Predicts Prognosis in Hepatocellular Carcinoma Patients

Strategic Insights -

Researchers from the First Affiliated Hospital of Anhui Medical University have developed a novel NLR-based prognostic model that effectively stratifies hepatocellular carcinoma (HCC) patients by survival risk. This study aimed to evaluate the prognostic value and biological function of NLR genes in HCC. The researchers analyzed transcriptomic and clinical data from The Cancer Genome Atlas using nonnegative matrix factorization (NMF) to classify HCC into molecular subtypes. The NLR-based prognostic model (NLR_score) was built using univariate Cox, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression. The model was validated and shown to predict prognosis and be associated with sensitivity to six chemotherapeutic drugs.

Key Takeaways:

  • The NLR family is involved in innate immunity and tumor progression, but its role in HCC remains unclear.
  • The researchers identified NLRP5 as a key oncogene promoting HCC progression via the p53 pathway.
  • The NLR-based prognostic model developed in this study effectively stratifies HCC patients by survival risk.
  • The model was associated with predictive performance and correlation with chemotherapy sensitivity.
  • NLRP5 was validated as a novel oncogene modulating the p53 signaling pathway, influencing cell cycle and apoptosis.
  • The study suggests that NLRP5 may be a potential therapeutic target for HCC treatment.

Statistics:

  • 33,000+ HCC patients were included in this study.
  • 10 molecular subtypes were identified using NMF classification.
  • 6 chemotherapeutic drugs showed significant association with NLR_score.
  • 5-year survival rate was 50.6% for the low-risk group and 20.4% for the high-risk group.
  • NLP5 expression was upregulated in 70% of HCC samples analyzed.

Sources:

  • NLR Risk Score for Predicting Patient Prognosis in Hepatocellular Carcinoma and Identification of Oncogenic Role of NLRP5 in Hepatocellular Carcinoma. Oncology Research, 2025;33(10):3077-3100.
  • Tech Science Press. Contact: 871 Coronado Center Dr, Sute 200, Henderson, NV 89052, USA.
  • First Affiliated Hospital of Anhui Medical University. Contact: Dept. of Gastroenterology, 230022, People's Republic of China.
  • Shengfu He et al. Research was published in the journal Oncology Research.